1 Lumos Pharma Inc Receivables Turnover Ratio (LUMO), from the third quarter 2024 to the third quarter 2023 current and historic results, rankings and more - CSIMarket

Company Name, Ticker, Customers, else..

Growth Rates

Profitability

Valuation Comparisons

Management Effectiveness

Financial Strength

Efficiency

• Sales per Employee

• Income per Employee

• Inventory Turnover

• Asset Turnover

• Receivables Turnover

Dividend Comparisons

Lumos Pharma Inc (NASDAQ: LUMO)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Lumos Pharma Inc Accounts Receivables Turnover Ratio from the third quarter 2024 to the third quarter 2023

Quarterly Results, Trends, Rankings, Statistics

Lumos Pharma Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the third quarter 2024 to a ratio of 12.03, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the third quarter 2024. Average receivable collection period, for the Lumos Pharma Inc in Sep 30 2024 quarter, has decreased to 30 days, compared to 45 days, in the Jun 30 2024 quarter.

If we take a look into Healthcare sector 537 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Sep 30 2024 from 927 to 3550.

What is Receivable Turnover Ratio?
What is Lumos Pharma Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

LUMO Receivables Turnover Ratio	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter
Y / Y Receivable Change	1.16 %	-27.9 %	-9.5 %	-5.83 %	-
Y / Y Revenue Change	10271.43 %	-7.4 %	-76.12 %	61.33 %	-98.59 %
Receivable Turnover Ratio (TTM)	12.03	8.13	7.66	10.07	8.39
LUMO's Total Ranking	# 3550	# 927	# 2924	# 1181	# 3305
Accounts Receivable average collection period days	30	45	48	36	43
Seq. Receivable Change	3.57 %	-7.18 %	-13.81 %	22.09 %	-26.18 %
Seq. Revenue Change	48.77 %	195.76 %	-80.02 %	11700 %	-98.67 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 192
Healthcare Sector	# 538
Overall Market	# 3550

Receivable Turnover Ratio Statistics
High	Average	Low
1.38	0.17	-0.03
(Dec 31 2014)		(Jun 30 2013)

LUMO Company Profile • Back to LUMO Efficiency Comparisons • Compare LUMO Receivables Turnover Ratio to its Competitors

Financial Statements
Lumos Pharma Inc 's Accounts Receivable	$ 0 Millions	Visit LUMO's Balance sheet
Lumos Pharma Inc 's Sales TTM	$ 2 Millions	Visit LUMO's Income Statement
Sources of LUMO's Revenues		Visit LUMO's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
LUMO's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
LUMO's Growth Rates	LUMO's Roa	LUMO's Inventory Turnover Ratio	LUMO's Dividend Comparisons
LUMO's Profitability Ratios	LUMO's Roi	LUMO's Asset Turnover Ratio	LUMO's Dividend Growth
LUMO's Valuation Ratios	LUMO's Roe	LUMO's Financial Strength Ratios	LUMO's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2024, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Sep 30 2024	Receivable at quarter ending Sep 30 2024
Ontrak Inc	34.00	$ 10.336 Millions	$ 0.304 Millions
Vivos Therapeutics Inc	33.86	$ 13.340 Millions	$ 0.394 Millions
Xoma Royalty Corporation	33.52	$ 21.606 Millions	$ 0.645 Millions
23andme Holding Co	33.34	$ 191.889 Millions	$ 5.756 Millions
Lifemd Inc	33.01	$ 192.420 Millions	$ 5.830 Millions
Eyepoint Inc	32.81	$ 45.713 Millions	$ 1.393 Millions
Clearside Biomedical Inc	32.16	$ 7.703 Millions	$ 0.240 Millions
Caribou Biosciences Inc	31.35	$ 11.475 Millions	$ 0.366 Millions
Invo Fertility Inc	29.95	$ 6.228 Millions	$ 0.208 Millions
Cv Sciences Inc	29.75	$ 14.867 Millions	$ 0.500 Millions
Orchestra Biomed Holdings Inc	29.33	$ 2.647 Millions	$ 0.090 Millions
Adaptimmune Therapeutics Plc	29.10	$ 175.041 Millions	$ 6.015 Millions
National Vision Holdings Inc	29.03	$ 1,952.174 Millions	$ 67.248 Millions
Aquestive Therapeutics Inc	27.81	$ 58.900 Millions	$ 2.118 Millions
Sonida Senior Living Inc	27.68	$ 278.115 Millions	$ 10.046 Millions
Renalytix Plc	27.67	$ 2.352 Millions	$ 0.085 Millions
Neuraxis Inc	27.03	$ 2.456 Millions	$ 0.091 Millions
Fortrea Holdings Inc	26.41	$ 2,774.800 Millions	$ 105.050 Millions
Dih Holding Us Inc	25.89	$ 116.794 Millions	$ 4.511 Millions
Anika Therapeutics Inc	24.69	$ 162.681 Millions	$ 6.590 Millions
Lineage Cell Therapeutics Inc	23.85	$ 8.719 Millions	$ 0.366 Millions
Agenus Inc	23.56	$ 160.428 Millions	$ 6.810 Millions
Kymera Therapeutics Inc	23.35	$ 87.563 Millions	$ 3.750 Millions
Editas Medicine Inc	22.87	$ 61.758 Millions	$ 2.701 Millions
U S Physical Therapy Inc	22.39	$ 645.699 Millions	$ 28.841 Millions
Bespoke Extracts Inc	22.31	$ 1.080 Millions	$ 0.048 Millions
Cytomx Therapeutics Inc	22.28	$ 126.617 Millions	$ 5.684 Millions
One World Products Inc	22.21	$ 0.003 Millions	$ 0.000 Millions
Igc Pharma Inc	21.71	$ 1.183 Millions	$ 0.054 Millions
Innovative Eyewear Inc	21.65	$ 1.562 Millions	$ 0.072 Millions

Date modified: 2026-09-26T07:12:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.